Neuren Pharmaceuticals Ltd
NEU
Company Profile
Business description
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
Contact
697 Burke Road
Suite 201
Camberwell
MelbourneVIC3124
AUST: +61 390920480
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
19
Stocks News & Analysis
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
stocks
This might be the best core stock bargain in the US market today
Patient investors should consider building a position in this wide-moat stock while it’s seriously undervalued.
stocks
Data center demand drives strong earnings outlook for SGM
Sims guides huge earnings upgrade as data center metals demand spikes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,552.60 | 77.00 | 0.91% |
| CAC 40 | 7,521.58 | 144.04 | -1.88% |
| DAX 40 | 21,937.55 | 442.64 | -1.98% |
| Dow JONES (US) | 45,577.47 | 443.96 | -0.96% |
| FTSE 100 | 9,694.30 | 224.03 | -2.26% |
| HKSE | 24,382.47 | 894.85 | -3.54% |
| NASDAQ | 21,647.61 | 443.08 | -2.01% |
| Nikkei 225 | 51,515.49 | 1,857.04 | -3.48% |
| NZX 50 Index | 12,899.72 | 90.27 | -0.69% |
| S&P 500 | 6,506.48 | 100.01 | -1.51% |
| S&P/ASX 200 | 8,365.90 | 82.40 | 0.99% |
| SSE Composite Index | 3,813.28 | 143.77 | -3.63% |